JP5960712B2 - アミノグリコシドおよび遺伝性障害の処置におけるその使用 - Google Patents

アミノグリコシドおよび遺伝性障害の処置におけるその使用 Download PDF

Info

Publication number
JP5960712B2
JP5960712B2 JP2013539397A JP2013539397A JP5960712B2 JP 5960712 B2 JP5960712 B2 JP 5960712B2 JP 2013539397 A JP2013539397 A JP 2013539397A JP 2013539397 A JP2013539397 A JP 2013539397A JP 5960712 B2 JP5960712 B2 JP 5960712B2
Authority
JP
Japan
Prior art keywords
compound
compounds
group
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013539397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542981A (ja
JP2013542981A5 (enExample
Inventor
ティモール バアソヴ，
ティモール バアソヴ，
ダナ アティア−グリキン，
ダナ アティア−グリキン，
ジェヤクマール カンダサミー，
ジェヤクマール カンダサミー，
ヴァレリー ベラコフ，
ヴァレリー ベラコフ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technion Research and Development Foundation Ltd
Original Assignee
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research and Development Foundation Ltd filed Critical Technion Research and Development Foundation Ltd
Publication of JP2013542981A publication Critical patent/JP2013542981A/ja
Publication of JP2013542981A5 publication Critical patent/JP2013542981A5/ja
Application granted granted Critical
Publication of JP5960712B2 publication Critical patent/JP5960712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D79/00—Kinds or details of packages, not otherwise provided for
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/228—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings
    • C07H15/23—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings with only two saccharide radicals in the molecule, e.g. ambutyrosin, butyrosin, xylostatin, ribostamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2013539397A 2010-11-18 2011-11-17 アミノグリコシドおよび遺伝性障害の処置におけるその使用 Active JP5960712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41495610P 2010-11-18 2010-11-18
US61/414,956 2010-11-18
PCT/IL2011/000889 WO2012066546A1 (en) 2010-11-18 2011-11-17 Aminoglycosides and uses thereof in treating genetic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016011038A Division JP2016121168A (ja) 2010-11-18 2016-01-22 アミノグリコシドおよび遺伝性障害の処置におけるその使用

Publications (3)

Publication Number Publication Date
JP2013542981A JP2013542981A (ja) 2013-11-28
JP2013542981A5 JP2013542981A5 (enExample) 2014-12-11
JP5960712B2 true JP5960712B2 (ja) 2016-08-02

Family

ID=45390144

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013539397A Active JP5960712B2 (ja) 2010-11-18 2011-11-17 アミノグリコシドおよび遺伝性障害の処置におけるその使用
JP2016011038A Pending JP2016121168A (ja) 2010-11-18 2016-01-22 アミノグリコシドおよび遺伝性障害の処置におけるその使用
JP2018036281A Active JP6758338B2 (ja) 2010-11-18 2018-03-01 アミノグリコシドおよび遺伝性障害の処置におけるその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016011038A Pending JP2016121168A (ja) 2010-11-18 2016-01-22 アミノグリコシドおよび遺伝性障害の処置におけるその使用
JP2018036281A Active JP6758338B2 (ja) 2010-11-18 2018-03-01 アミノグリコシドおよび遺伝性障害の処置におけるその使用

Country Status (18)

Country Link
US (7) US8895519B2 (enExample)
EP (2) EP2640734B1 (enExample)
JP (3) JP5960712B2 (enExample)
CA (1) CA2816789C (enExample)
CY (1) CY1120082T1 (enExample)
DK (1) DK2640734T3 (enExample)
ES (2) ES2833938T3 (enExample)
HR (1) HRP20180056T1 (enExample)
HU (1) HUE036248T2 (enExample)
IL (3) IL266495B (enExample)
LT (1) LT2640734T (enExample)
NO (1) NO2640734T3 (enExample)
PL (1) PL2640734T3 (enExample)
PT (1) PT2640734T (enExample)
RS (1) RS56739B1 (enExample)
SI (1) SI2640734T1 (enExample)
SM (1) SMT201800019T1 (enExample)
WO (1) WO2012066546A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121168A (ja) * 2010-11-18 2016-07-07 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド アミノグリコシドおよび遺伝性障害の処置におけるその使用
US10576095B2 (en) 2014-06-05 2020-03-03 Eloxx Pharmaceuticals Ltd. Use of aminoglycoside analogs in the treatment of Rett syndrome

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101703137B1 (ko) 2014-05-30 2017-02-07 선문대학교 산학협력단 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
EP3344641A4 (en) * 2015-09-02 2019-09-18 Eloxx Pharmaceuticals Ltd. AMINO-LIKES DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF GENETIC DISEASES
US11306115B2 (en) 2015-09-02 2022-04-19 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
EP3350194A4 (en) 2015-09-02 2019-04-24 Eloxx Pharmaceuticals Ltd. AMINO-LIKES DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF GENETIC DISEASES
WO2017118968A1 (en) * 2016-01-05 2017-07-13 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
CN117466958A (zh) * 2017-03-15 2024-01-30 Eloxx制药有限公司 假三糖氨基糖苷及其中间体的大规模制备
WO2019237076A1 (en) * 2018-06-07 2019-12-12 Eloxx Pharmaceuticals, Inc. Methods, compositions, and kits for inducing readthrough
KR102067477B1 (ko) * 2018-06-20 2020-01-17 고려대학교 산학협력단 스킬로이노사민을 포함하는 아미노사이클리톨 화합물, 이의 제조방법 및 이를 함유하는 약학 조성물
AU2019387385A1 (en) * 2018-11-29 2021-07-08 Eloxx Pharmaceuticals Methods, compositions, and kits for treating ocular diseases
WO2021061873A1 (en) * 2019-09-23 2021-04-01 Eloxx Pharmaceuticals, Inc. Methods, compositions, and kits for treating polycystic kidney disease
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5960712A (ja) 1982-09-30 1984-04-06 Toshiba Corp デ−タ判別装置
WO2005078099A1 (en) 2004-02-17 2005-08-25 The Hospital For Sick Children Mecp2e1 gene
EP2390255B1 (en) * 2006-04-03 2016-07-13 Technion Research & Development Foundation Ltd. Novel aminoglycosides and uses thereof in the treatment of genetic disorders
SI2640734T1 (en) * 2010-11-18 2018-02-28 Technion Research & Development Foundation Ltd. Aminoglycosides and their uses in the treatment of genetic disorders
JP2017516835A (ja) * 2014-06-05 2017-06-22 エロックス ファーマシューティカルズ リミテッド レット症候群治療におけるアミノグリコシド類縁体の使用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121168A (ja) * 2010-11-18 2016-07-07 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド アミノグリコシドおよび遺伝性障害の処置におけるその使用
US9943533B2 (en) 2010-11-18 2018-04-17 Technion Research & Development Foundation Limited Aminoglycosides and uses thereof in treating genetic disorders
US10398718B2 (en) 2010-11-18 2019-09-03 Technion Research & Development Foundation Limited Aminoglycosides and uses thereof in treating genetic disorders
US10973839B2 (en) 2010-11-18 2021-04-13 Technion Research & Development Foundation Limited Aminoglycosides and uses thereof in treating genetic disorders
US11865128B2 (en) 2010-11-18 2024-01-09 Technion Research & Development Foundation Limited Aminoglycosides and uses thereof in treating genetic disorders
US10576095B2 (en) 2014-06-05 2020-03-03 Eloxx Pharmaceuticals Ltd. Use of aminoglycoside analogs in the treatment of Rett syndrome

Also Published As

Publication number Publication date
CY1120082T1 (el) 2018-12-12
IL266495A (en) 2019-07-31
ES2833938T3 (es) 2021-06-16
US20170182078A1 (en) 2017-06-29
SI2640734T1 (en) 2018-02-28
CA2816789C (en) 2018-12-11
PT2640734T (pt) 2018-01-22
US9175029B2 (en) 2015-11-03
US20210228608A1 (en) 2021-07-29
EP2640734A1 (en) 2013-09-25
IL266495B (en) 2020-09-30
US20130237489A1 (en) 2013-09-12
CA2816789A1 (en) 2012-05-24
WO2012066546A1 (en) 2012-05-24
JP6758338B2 (ja) 2020-09-23
US11865128B2 (en) 2024-01-09
EP3296311A1 (en) 2018-03-21
HK1248709A1 (en) 2018-10-19
JP2016121168A (ja) 2016-07-07
US9616079B2 (en) 2017-04-11
ES2655916T3 (es) 2018-02-22
HRP20180056T1 (hr) 2018-02-09
US20180200276A1 (en) 2018-07-19
JP2013542981A (ja) 2013-11-28
IL284067A (en) 2021-07-29
US10398718B2 (en) 2019-09-03
PL2640734T3 (pl) 2018-04-30
US9943533B2 (en) 2018-04-17
JP2018123135A (ja) 2018-08-09
SMT201800019T1 (it) 2018-03-08
EP3296311B1 (en) 2020-09-30
LT2640734T (lt) 2018-02-12
DK2640734T3 (en) 2018-01-22
RS56739B1 (sr) 2018-03-30
HUE036248T2 (hu) 2018-06-28
IL277063A (en) 2020-10-29
US20140357590A1 (en) 2014-12-04
US20160074425A1 (en) 2016-03-17
NO2640734T3 (enExample) 2018-03-17
EP2640734B1 (en) 2017-10-18
US20190224226A9 (en) 2019-07-25
IL277063B (en) 2021-07-29
US8895519B2 (en) 2014-11-25
US20200078386A1 (en) 2020-03-12
IL284067B (en) 2022-03-01
US10973839B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
JP5960712B2 (ja) アミノグリコシドおよび遺伝性障害の処置におけるその使用
JP5345928B2 (ja) 新規なアミノグリコシド類および遺伝子疾患の治療におけるその使用
JP6862428B2 (ja) アミノグリコシド誘導体および遺伝性疾患の治療におけるその使用
JP2018528211A5 (enExample)
HK1248709B (en) Aminoglycosides and uses thereof in treating genetic disorders
HK1190157A (en) Aminoglycosides and uses thereof in treating genetic disorders
HK1190157B (en) Aminoglycosides and uses thereof in treating genetic disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160623

R150 Certificate of patent or registration of utility model

Ref document number: 5960712

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250